Prodrugs of prostate specific membrane antigen (PSMA) inhibitor

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F18%3A00501191" target="_blank" >RIV/61388963:_____/18:00501191 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=US&NR=9988407B2&KC=B2&FT=D&ND=4&date=20180605&DB=&locale=en_EP#" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=US&NR=9988407B2&KC=B2&FT=D&ND=4&date=20180605&DB=&locale=en_EP#</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Prodrugs of prostate specific membrane antigen (PSMA) inhibitor
Original language description
Various structural types of prodrugs of 2-phosphonomethylpentanedioic acid were synthesized as GCPII inhibitors. The prodrug with the optimal pharmacokinetic profile was obtained by introducing POC groups on both the phosphonate and α-carboxylate. Thus formed Tris-POC-2-PMPA afforded excellent release of parent 2-PMPA following oral administration in both mice and dog.
Czech name
—
Czech description
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Patent/design ID
US9988407
Publisher
US001 -
Publisher name
United States Patent and Trademark Office (USPTO)
Place of publication
Alexandria
Publication country
US - UNITED STATES
Date of acceptance
Jun 5, 2018
Owner name
The Johns Hopkins University - Ústav organické chemie a biochemie AV ČR, v. v. i
Method of use
B - Výsledek je využíván orgány státní nebo veřejné správy
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence

Similar results(10)